ReviewIndian pediatrics2025
Current Status of Ultra Long-Acting Beta Agonists in Children.
Review in Indian pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultra long-acting beta-agonists (ULABAs) have emerged as key therapeutic agents in the management of chronic obstructive pulmonary disease (COPD) and asthma, offering prolonged bronchodilation and symptom control in adults. Their extended duration of action, often exceeding 24 h, reduces the need for frequent dosing, enhancing adherence and simplifying treatment regimens. However, the use of ULABAs in children presents unique challenges, including age-specific pharmacodynamics, safety concerns, and the need for appropriate combination therapies with inhaled corticosteroids. Current research suggests potential benefits in improving lung function and the quality of life, yet robust evidence remains limited. Regulatory guidelines vary, emphasizing the cautious application of ULABAs in children, particularly under 12 years, due to concerns about adverse effects and optimal dosing. Future research should address these gaps, focusing on long-term safety, efficacy, and the role of personalized approaches to optimize asthma outcomes in this vulnerable population.
Indexed as
Identifiers
40699447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.